JIUXIANZUN Dendrobium Huoshanense: Bridging Sino-French Health Traditions with Eastern Wisdom
Intangible Cultural Heritage Meets the World: CEO Shares a Philosophy of Health
At the Sino-French Exchange Conference in Paris, Ms. Zhang Shuhua, CEO of the JIUXIANZUN brand, offered international guests an in-depth introduction to the millennia-old tradition of wellness in traditional Chinese medicine through Dendrobium Huoshanense, along with the story of her 15-year journey to cultivate and revive this revered "immortal herb." Her story resonated strongly with French guests and media, aligning with their values of balance and natural healing.
At the banquet, guests sampled products from JIUXIANZUN and the Hu Mama Dendrobium series, praising their delicate aroma, versatile pairing options, and exceptional health benefits.
International Certifications Demonstrate Strength; Ecological Value Gains Global Recognition
As the industry standard-setter for Dendrobium Huoshanense in China, JIUXIANZUN has built a reputation for excellence through its expansive ecological base covering tens of thousands of acres, 13 consecutive years of organic certification, and multiple national patents. By establishing a "forest-floor, stone-based" semi-wild cultivation system, the company faithfully recreates the authentic growing conditions recorded in ancient texts. This commitment has earned significant international recognition. French guests praised the products as "a perfect blend of scientific rigor and cultural warmth, offering an Eastern solution for global health."
China's "Immortal Herb," Dendrobium Huoshanense, Poised to Become a New Global Symbol of Health
With Sino-French traditional medicine collaboration projects growing by 40% annually (according to WHO data), Dendrobium Huoshanense is steadily gaining international prominence. Through continuous exchange and integration, it is becoming a vital bridge connecting traditional Chinese medicine with global health needs, infusing Eastern wellness wisdom into European lifestyles.
"We are creating a new language of health that transcends cultural boundaries," said Zhang Shuhua, envisioning this millennia-old herb as the next global superfood.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
2 hours ago
- Scientific American
Organs Age in Waves Accelerating at 50 Years Old
It is a warning that middle-aged people have long offered the young: ageing is not a smooth process. Now, an exhaustive analysis of how proteins change over time in different organs backs up that idea, finding that people experience an inflection point at around 50 years old, after which ageing seems to accelerate. The study, published 25 July in Cell, also suggests that some tissues — especially blood vessels — age faster than others, and it identifies molecules that can hasten the march of time. The findings add to mounting evidence that ageing is not linear, but is instead pockmarked by periods of rapid change. Even so, larger studies are needed before scientists can label the age of 50 as a crisis point, says Maja Olecka, who studies ageing at the Leibniz Institute on Aging — Fritz Lipmann Institute in Jena, Germany, and was not involved in the study. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. 'There are these waves of age-related changes,' she says. 'But it is still difficult to make a general conclusion about the timing of the inflection points.' Showing their age Previous work has shown that different organs can age at different rates. To further unpick this, Guanghui Liu, who studies regenerative medicine at the Chinese Academy of Sciences in Beijing, and his colleagues, collected tissue samples from 76 people of Chinese ancestry aged 14 to 68 who had died from accidental brain injury. The samples came from organs representing eight of the body's systems, including the cardiovascular, immune and digestive systems. The researchers then created a compendium of the proteins found in each of the samples. They found age-related increases in the expression of 48 disease-associated proteins, and saw early changes at around age 30 in the adrenal gland, which is responsible for producing various hormones. This tracks well with previous data, says Michael Snyder, a geneticist at the Stanford University School of Medicine in California. 'It fits the idea that your hormonal and metabolic control are a big deal,' he says. 'That is where some of the most profound shifts occur as people age.' Between the ages of 45 and 55 came a turning point marked by large changes in protein levels. The most dramatic shift was found in the aorta, the body's main artery, which carries oxygenated blood out of the heart. The team tracked down one protein produced in the aorta that, when administered to mice, triggers signs of accelerated ageing. Liu speculates that blood vessels act as a conduit, carrying molecules that promote ageing to remote destinations throughout the body. The study is an important addition to others that have analysed molecules circulating in the blood, rather than tissue samples taken from individual organs, as a way to monitor age-related changes, says Snyder. 'We're like a car,' he says. 'Some parts wear out faster.' Knowing which parts are prone to wear and tear can help researchers to develop ways to intervene to promote healthy ageing, he says. Halfway to 100 Last year, Snyder and his colleagues found ageing inflection points around the ages of 44 and 60. Other studies have found accelerated ageing at different times, including at around 80 years old, which was beyond the scope of the current study, says Olecka. Discrepancies with other studies can emerge from their use of different kinds of samples, populations and analytical approaches, says Liu. As data build over time, key molecular pathways involved in ageing will probably converge across studies, he adds. These data will accumulate rapidly, says Olecka, because researchers are increasingly incorporating detailed time series in their studies, rather than simply comparing 'young' with 'old'. And those results could help researchers to interpret these periods of rapid change. 'Currently, we do not understand what triggers this transition point,' she says. 'It's a really intriguing emerging field.'
Medscape
2 hours ago
- Medscape
Cloud Coffee: A Viral Drink That May Be a Healthy Choice
Another day, another viral TikTok drink. The beverage making the rounds right now is cloud coffee. The name alone sounds light and refreshing, which is exactly what many of us look for in a summer coffee drink. But what is actually in it, and is it any good for us? Cloud coffee is a chilled espresso drink made by layering Dalgona coffee over coconut water to yield a cold coffee beverage that is as beautiful as it is refreshing. Dalgona coffee, which originated in Macau in Southern China, consists of coffee powder, hot water, and sugar well beaten and layered over milk. It can be served hot or cold and it was named after the Korean candy that shares its caramel color. This whipped 'cloud' mixture is poured over a base of ice and coconut water, inspired by the coconut water americano that was also popular this spring. A coconut water americano is a simple drink that combines coconut water and espresso for a refreshing cold coffee beverage. Health Benefits From iced coffee to mocha protein shakes, the summertime coffee drinker in us is always happy with a chilled treat with a bit of caffeine. The question is, how healthy is this coffee swap for our chronic coffee drinkers? As with most things, it can be a good choice in moderation. A 16-ounce serving with 2 teaspoons of sugar contains about 150 calories, 5 g of protein, and even with a double shot of espresso, only about 120 mg of caffeine. That's comparable to the caffeine in a 12-ounce drip coffee. The addition of coconut water makes it a good source of potassium, a nutrient that is underconsumed by most Americans. Coffee is known around the world for its effect on cognition and energy levels, but it is also high in antioxidants. Caffeine and chlorogenic acid can promote a decrease in oxidative stress and improve inflammation. A pretty great way to start a hot summer day! While some recipes call for cream, I recommend whole fat milk to ensure adequate creaminess while incorporating more protein. Protein and fat both promote satiety, and a high protein diet can promote weight loss. Protein also has the added benefit of slowing down digestion and thus absorption of caffeine to allow for a slower uptake of caffeine over a longer time. This may help maintain energy levels and reduce any unpleasant side effects of caffeine such as elevated blood pressure. While I don't often recommend artificial sweeteners, the sugar in this drink could be swapped for aspartame or stevia without affecting the integrity of the whipped Dalgona coffee for those who prefer a sugar-free option. Maybe Not for Everyone While such a beverage is likely to be a refreshing treat for most, it may not be appropriate for all. Caffeine-containing beverages may not be the right choice for those prone to gastrointestinal issues like irritable bowel syndrome with diarrhea due to the stimulating effects of caffeine on the bowel or on those with high blood pressure due to its properties as a vasoconstrictor. Caffeine is a well-known diuretic, so I typically recommend limiting caffeine-containing beverages to no more than 2 or 3 a day, especially during the warm summer months when we may be more at risk of dehydration. Healthy and Refreshing Alternatives As cloud coffee may not be the right choice for everyone, I always like to have a few alternatives that are either low in caffeine or caffeine-free to encourage hydration. I have many clients who drink coffee all day long, so I have a couple of tricks to help them stay hydrated without completely giving up their caffeine or adding a lot of sugar. Green tea: Green tea has less than half the caffeine that coffee does and significantly more antioxidants, most in the form of epigallocatechin gallate that has been shown to promote weight loss and improve glucose metabolism. Hibiscus tea: Hibiscus tea is caffeine free and may help to improve mild hypertension. Caffeinated sparkling water: Many brands have less caffeine per serving than a cup of coffee and can also be a great substitute for chronic soda drinkers. Iced coffee with a protein shake: This may be especially helpful for those who are in the habit of drinking several cups of coffee a day. Mix 8 ounces of cold brewed coffee with a 12-ounce protein shake for less caffeine over several hours to stay focused while decreasing the unpleasant side effects of caffeine intake. Ultimately, I want my clients to drink water for hydration in the warm summer months. But, if a fun and refreshing coffee drink like cloud coffee has them excited and offers a few health benefits as well, I'm on board.
Yahoo
4 hours ago
- Yahoo
Theraclion Growth Up in S1 2025
MALAKOFF, France, July 25, 2025--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reviews its business for S1 2025. Sales of consumables (recurring revenue) up 30% compared to 2024 New treatment centers opened in Bulgaria and Spain Appointment of a new business manager and acceleration of commercial activities On-schedule completion of the follow-up period for the pivotal FDA clinical trial Martin Deterre, CEO of Theraclion, states: "In early 2025, Theraclion stepped up Sonovein's activity. In June, the final 12-month follow-ups for patients in the pivotal FDA-approved clinical trial were completed on-schedule. We are now awaiting the final results, which we expect to publish in September. Theraclion has also entered a business development phase: building a sales and marketing team, opening two new Sonovein treatment centers, and achieving significant growth in recurring revenue — all of which promise the achievement of our ambitious goals." Commercial activity acceleration As part of its business development, Theraclion is actively building its sales and marketing team. In May 2025, Thibault Le Normand joined the company as Chief Business Officer to boost sales in the Middle East and product placements (PPUs) of Sonovein in Europe. With over a decade of experience in international development of medical devices, Thibault Le Normand brings valuable expertise to this strategic growth phase. At the same time, the technological credibility and clinical maturity of Sonovein have been further demonstrated by the publication of new scientific articles as well as by over a dozen presentations at major international congresses by renowned physicians using the device. Sonovein's international profile has also increased through Theraclion's participation in congresses, such as Vein in Venice (April, Venice), Venous Symposium (May, New York), and the European Venous Forum (June, Krakow). This outreach effort was supported by the launch of a new product identity and a new website, giving Sonovein a new brand image that reflects innovation, clinical excellence, and ambition. In addition, two new product placement (PPU) contracts for Sonovein have been signed in Bulgaria and Spain, stepping up Theraclion's presence in Europe and expanding the installed base of the technology. Revenue for S1 2025 In K€ 06/30/2025 06/30/2024 Var. % Revenue 835 -238 from the sale of components and systems 309 -572 from the sale of consumables 372 287 30% from the sale of services 153 46 232% Other operating revenue 17 138 -88% of which Veins 832 442 of which Breast and Thyroid 3 -680 Total operating revenue 852 -100 Theraclion's revenue for S1 2025 was €835K, up 89% compared to 2024 (€442K) (prior to the non-recurring adjustment of €680K related to the cancellation of Echopulse system sales in 2024). Consumables, which include recurring revenues from PPUs, was up 30% compared to S1 2024. Service revenues were up 232% over the same period. This strong momentum is a key indicator of increasing use of Sonovein by treatment centers and reflects the technology's sustained traction in the field. Combined, consumables and services — representing recurring revenue — was up 57% compared to 2024. Progress of the pivotal FDA clinical trial In the USA, the pivotal FDA-approved study for SONOVEIN® reached a major milestone in June 2025 with the on-schedule completion of the 12-month post-treatment patient follow-ups. Data analysis is currently underway, with results expected in September. Submission of the marketing authorization application to the FDA is planned for Fall 2025, with potential approval estimated for Q2 2026, subject to the FDA's processing time. This progress marks a critical strategic milestone in the work to access the world's largest market for venous disease treatment. Next financial publication: Theraclion will publish its interim financial results on October 29, 2025. About Theraclion Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and patients can immediately resume their routines. HIFU treatment concentrates therapeutic ultrasounds on an internal focal point from outside the body. Theraclion is developing SONOVEIN®, a CE-marked, a robotic platform for HIFU varicose vein treatment, which could replace millions of surgical procedures every year. In the USA, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the USA. Based in Malakoff (Paris), the Theraclion team comprises some 30 people, most of them involved in technological and clinical development. For more information, visit and follow LinkedIn account. Theraclion is listed on Euronext Growth ParisEligible for the PEA-PME schemeMnemonic: ALTHE - ISIN code: FR0010120402LEI: 9695007X7HA7A1GCYD29 View source version on Contacts Theraclion contact Martin DeterreChief Executive Officercontact@
